Ann: Ceasing to be a substantial holder from MS, page-11

BMS is forecast to get $1.5b revenue from Yervoy in 2018. If they can supercharge that with Cavatak, they could add billions to their revenue in the next 5+ years. I reckon they have enough incentive to move quickly. Others have more to gain (adding to their own pd-1/pd-l1 inhibitor that would otherwise not stand out) although their risk would be much greater with no combo trials in the bag yet.
Still plenty of opportunity for a counter bid yet!